Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967446 | 0.85 | MAPT (0.48) | ADRB1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL4283993 | 0.82 | POLB (0.46) | ADRB1MAPTMGLLMEN1KMT2A | |
| SCHEMBL3970586 | 0.69 | ADRA1A (0.35) | MAPTMEN1KMT2ALMNARAB9A | |
| SCHEMBL21262494 | 0.68 | ADRB1 (0.44) | F2ELANECTSGCMA1CTRC | |
| SCHEMBL31432954 | 0.67 | MAPT (0.67) | ADRB1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL13232537 | 0.67 | MAPT (0.67) | ADRB1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL9832282 | 0.67 | ADRB1 (0.47) | F2ELANECTSGCMA1CTRC | |
| SCHEMBL10063748 | 0.67 | ADRB1 (0.70) | ADRB1MAPTMEN1KMT2ALMNA | |
| SCHEMBL9678667 | 0.67 | ADRB1 (0.56) | F2ELANECTSGCMA1CTRC | |
| SCHEMBL7105773 | 0.67 | ADRB1 (0.70) | ADRB1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0866656-B1 | USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS | MARGOLIN SOLOMON B (US) | 2007-04-25 | — | — | EP | claimed |
| EP-0813409-B1 | TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS | MARGOLIN SOLOMON B (US) | 2004-05-06 | — | — | EP | claimed |
| US-5962478-A | ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE | INTERMUNE, INC. | 1999-10-05 | — | — | US | claimed |
| US-20250268821-A1 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | AVALYN PHARMA INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250177294-A1 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | AVALYN PHARMA INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250114376-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2025-04-10 | — | — | US | disclosed |
| US-12226407-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4491180-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | Avalyn Pharma Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-3091976-B1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12023342-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230330357-A1 | NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF | AVALYN PHARMA INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2012106382-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20060198823-A1 | Compositions and methods for treating viral infections | INTERMUNE, INC. | 2006-09-07 | — | — | US | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| US-5962478-A | ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE | INTERMUNE, INC. | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | F2 117/4885ELANE 649/4885CTSG 1716/4885 |
| US-20250268821-A1 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | INF2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IPO5 | F2 926/4885ELANE 283/4885CTSG 4087/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | F2 117/4885ELANE 649/4885CTSG 1716/4885 |
| US-20060198823-A1 | Compositions and methods for treating viral infections | IFNAR1, IFNG, TLR3 | F2 594/4885ELANE 1863/4885CTSG 621/4885 |
| US-20250114376-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | F2 166/4885ELANE 1574/4885CTSG 4667/4885 |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | F2 166/4885ELANE 1574/4885CTSG 4667/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | F2 117/4885ELANE 649/4885CTSG 1716/4885 |
| US-12023342-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | F2 166/4885ELANE 1574/4885CTSG 4667/4885 |
| US-20250177294-A1 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | INF2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IPO5 | F2 926/4885ELANE 283/4885CTSG 4087/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | F2 117/4885ELANE 649/4885CTSG 1716/4885 |
| US-12226407-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | F2 166/4885ELANE 1574/4885CTSG 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.